2-乙酰氨基甲基吡啶 | 58481-18-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-乙酰氨基甲基吡啶
• 英文名称: N-(pyridin-2-ylmethyl)acetamide
• 英文别名: 2-Acetamido-methyl-pyridin
• CAS: 58481-18-8
• 化学式: C₈H₁₀N₂O
• mdl: MFCD01195297
• 分子量: 150.18
• InChiKey: ACOHAEBNFWGQCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-乙酰氨基甲基吡啶 在 sodium hydride 、 间氯过氧苯甲酸 作用下， 以 溶剂黄146 为溶剂， 反应 18.0h， 生成 N-Acetyl-3-tert-butyl-N-(1-oxy-pyridin-2-ylmethyl)-4-tetradecyloxy-benzamide
  参考文献：
  名称：

  Analogs of platelet activating factor. 8. Antagonists of PAF containing an aromatic ring linked to a pyridinium ring

  摘要：

  A series of platelet activating factor (PAF) antagonists containing a quaternary pyridinium ring connected through an amide, imide, or carbamate linkage to a substituted aromatic ring was prepared. Of these compounds, those containing a branched imide linkage of the form (CON-(COCH3)CH2, 37-51, and 59) generally showed excellent PAF antagonist properties in vitro. Structure-activity relationships within this series of compounds were studied extensively with respect to substituents and the position of substitution in both the aromatic and pyridinium rings. Several of these compounds (40 and 44) showed in vitro PAF antagonism at less than 0.1 muM and are as potent as CV-6209, the most potent PAF antagonist reported in the literature. Less active PAF antagonists were those bearing simple amide linkages (20-23, 27-29, and 31-35), linear imide linkages (62-63), or carbamate linkages (66 and 68), between the two aromatic rings. A number of our PAF antagonists were tested in vivo in mice and rabbits for their ability to protect these animals against a lethal injection of PAF. Those antagonists that are particularly potent (IC50 <0.1 muM) provide excellent protection against an LD97 dose of PAF in rabbits. The relationships between structure and activity in vitro and in vivo are presented and compared to literature standards.

  DOI：

  10.1021/jm00057a008
• 作为产物：
  描述：

  2-氨甲基吡啶 在 吡啶 、 4-二甲氨基吡啶 、 乙酸酐 作用下， 生成 2-乙酰氨基甲基吡啶
  参考文献：
  名称：

  Pyridinium compounds which are useful as antagonists of platelet

  摘要：

  这项发明是有机芳基、酰胺、亚胺和碳酸酯吡啶拮抗剂，用于抑制血小板活化因子。

  公开号：

  US05208247A1
• 作为试剂：
  描述：

  4-碘联苯 、 FMOC-N-甲基-L-丙氨酸 在 2-乙酰氨基甲基吡啶 、 palladium diacetate 、 silver carbonate 作用下， 以48 %的产率得到(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-([1,1'-biphenyl]-4-yl)propanoic acid
  参考文献：
  名称：

  羧酸盐导向的 Pd 催化 N-甲基丙氨酸衍生物的 β-C(sp3)–H 芳基化用于生物活性肽的多样化

  摘要：

  本研究提出了一种 Pd(II) 催化的N -Cbz- 或N -Fmoc-保护的N-甲基丙氨酸的 β-C(sp 3 )–H 芳基化方法，为N-甲基化肽的构建模块提供了方便的途径合成。对于这种转化，利用天然羧酸盐作为导向基团，将其成功归因于单保护的氨基-吡啶配体的使用。通过轻松生成天然存在的N-甲基化环肽环肽 A 的九种类似物，证明了其合成效用。

  DOI：

  10.1021/acs.orglett.3c03616

文献信息

• [EN] SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS<br/>[FR] ANALOGUES D'URÉE PONTÉS SUBSTITUÉS EN TANT QUE MODULATEURS DE SIRTUINE
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2016079709A1

  公开（公告）日：2016-05-26

  The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

  本发明涉及一种新型的取代桥式脲类似物化合物，其化学式为（I）或其药学上可接受的盐，相应的药物组合物，制备这种化合物的方法以及单独使用或与其他治疗剂联合使用的这些化合物作为Sirtuin调节剂，可用于增加细胞寿命，并用于治疗和/或预防各种疾病和紊乱，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块紊乱、炎症、癌症和/或潮红有关的疾病或紊乱，以及那些会受益于增加线粒体活性的疾病或紊乱。
• HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS
  申请人：CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD.

  公开号：US20170253614A1

  公开（公告）日：2017-09-07

  A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

  一系列丙型肝炎病毒（HCV）抑制剂及其组合物，以及在制备用于治疗慢性HCV感染的药物时的应用。特别是一系列用作NS5A抑制剂的化合物，以及在药物制剂中的组合物和用途。
• METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS AND VIRAL INFECTIONS
  申请人：University College Dublin, National University of Ireland, Dublin

  公开号：US20160102051A1

  公开（公告）日：2016-04-14

  The invention generally relates to methods and compounds for treating proliferative disorders, viral infections, or both. In some embodiments, the invention provides an anticancer or antiviral compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating a proliferative disorder or a viral infection including administering an anticancer or antiviral compound that binds to a thromboxane receptor, has preferential binding for either TPalpha (TPα) or TPbeta (TPβ) receptor subtype.

  这项发明通常涉及用于治疗增殖性疾病、病毒感染或两者的方法和化合物。在某些实施例中，该发明提供了一种抗癌或抗病毒化合物，包括一种取代硝基苯氧基苯基、磺酰脲和烷基。在某些实施例中，该发明提供了一种治疗增殖性疾病或病毒感染的方法，包括给予一种结合到血栓素A2受体、对TPalpha（TPα）或TPbeta（TPβ）受体亚型具有优先结合的抗癌或抗病毒化合物。
• New half-sandwich (η6-p-cymene)ruthenium(II) complexes with benzothiazole hydrazone Schiff base ligand: Synthesis, structural characterization and catalysis in transamidation of carboxamide with primary amines
  作者：Subbarayan Vijayapritha、Periasamy Viswanathamurthi

  DOI：10.1016/j.jorganchem.2020.121555

  日期：2020.12

  techniques (IR, NMR) and also by mass spectrometry. The solid state structure of the complex 3 reveals the coordination of p-cymene moieties with ruthenium(II) in a three-legged piano-stool geometry along with benzothiazole hydrazone Schiff base ligand in a monobasic bidentate fashion. The catalytic properties of the complexes were screened in transamidation of primary amide with amines after optimization

  几个半夹心（η 6 -对-伞花烃）钌（II）苯并噻唑由腙Schiff碱负载的络合物合成的。新配合物具有通式的[Ru（η 6 -对-甲基异丙基苯）（L）CL]（1 - 3）（L =水杨基（（2-（苯并噻唑-2-基）亚肼基）甲基苯酚）（SAL-HBT ），2-（（（2-（苯并噻唑-2-基）肼基）甲基）-6甲氧基苯酚）（VAN-HBT）或萘基-2-（（2-（苯并噻唑-2-基）肼基）甲基苯酚）（ NAP-HBT）。所有化合物均通过分析，光谱技术（IR，NMR）以及质谱进行了全面研究。配合物3的固态结构揭示了p-在三脚钢琴凳几何形状中与钌（II）并用苯并噻唑Schiff碱配体的二茂基部分以及二元二齿形式。在优化溶剂，取代基，时间和催化剂载量后，在伯酰胺与胺的氨基转移中筛选配合物的催化性能。结果表明，配合物3是羧酰胺与胺进行氨基转移的最有效催化剂。
• [EN] TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS<br/>[FR] INHIBITEURS DE PRMT5 DÉRIVÉS DE TÉTRAHYDROISOQUINOLÉINE
  申请人：CTXT PTY LTD

  公开号：WO2016034673A1

  公开（公告）日：2016-03-10

  A compound of formula I wherein: n is 1 or 2: p is 0 or 1; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.

  式I的化合物，其中：n为1或2；p为0或1；R1可选地为一个或多个卤素或甲基基团；R2a和R2b分别选自以下组：(i) F；(ii) H；(iii) Me；和(iv) CH2OH；R2c和R2d分别选自以下组：(i) F；(ii) H；(iii) Me；和(iv) CH2OH；R3a和R3b分别选自H和Me；R4为H或Me；R5为H或Me；R6a和R6b分别选自H和Me；A为(i)可选地取代的苯基；(ii)可选地取代的萘基；或(iii)可选地取代的C5-12杂环基。